Bayer Wins US Approval for New Drug Hyrnuo in Lung Cancer

Bayer AG won US approval for its new medicine Hyrnuo to treat a common form of lung cancer as the German company works to bolster its drug pipeline.

The US Food and Drug Administration cleared the treatment for adults with non-squamous non-small-cell lung cancer whose tumors are advanced or have spread and carry mutations of HER2 — a gene often associated with breast cancer. The medicine got an accelerated approval, meaning the company may need to perform another clinical trial to confirm its benefits.